Neurogenesis is the process by which neurons are created. This process is most active during pre-natal development when neurogenesis is responsible for populating the growing brain.
Neural stem cells (NSCs) are the self-renewing, multipotent cells that differentiate into the main phenotypes of the nervous system. These cell types include neurons, astrocytes, and oligodendrocytes. Neural progenitor cells (NPCs) are the progeny of stem cell division that normally undergo a limited number of replication cycles in vivo.
In 1992, Reynolds and Weiss were the first to isolate neural stem cells from the striatal tissue of adult mice brain tissue, including the subventricular zone, which is a neurogenic area. Since then, neural progenitor and stem cells have been isolated from various areas of the adult brain, including non-neurogenic areas like the spinal cord, and from other species, including humans.
During the development of the nervous system, neural progenitor cells can either stay in the pool of proliferating undifferentiated cells or exit the cell cycle and differentiate. The past twenty years have seen great advances in neural stem cell research and applications. Researchers have isolated NSCs, which have demonstrated pluripotency and the ability to differentiate into many different immune system cell types.
The Market for Neural Stem Cell Products
NSCs can be regulated both in vitro and in vivo, which represent different commercial product opportunities. Neural stem cells have also become of profound interest to the research community, due to their potential to be used in drug discovery and delivery applications, as well as for tools of neural toxicology assessment.
NSC transplantation also represents a ground-breaking approach for treating a range of chronic neurological diseases and acute CNS injuries, including Parkinson’s, Alzheimer’s, spinal cord injury, and other conditions.
Furthermore, neural stem and progenitor cells offer the potential to safely carry out pharmacology assessment for drugs designed to impact brain function or physiology. As tests on human cells become increasingly feasible, the potential grows for companies to develop disease-specific cell assays by producing recombinant stem cell lines expressing a therapeutic target.
As novel drug delivery agents, neural stem cells also show promise in killing gliomas and other cancers. Finally, viable therapies for treating disease through neural stem cell transplantation are also on the horizon for forward-thinking researchers.
Growth in stem cell research has exploded over the past two decades, and the market to supply neural stem cell products and therapies has grown to meet this huge demand. The proliferation of neural stem cell research since 1992 has opened the floodgates for forward-thinking companies to enter a unique product and technology marketplace.
Launching March 2016, the market report “Strategic Development of Neural Stem and Progenitor Cell Products” will to reveal the current and future needs of the neural stem cell marketplace, so you can focus your marketing efforts on the most profitable products, in the most promising research areas, within the most lucrative domestic and international markets.
Key findings within this report include:
(Neural Stem Cell = NSC)
- Recent Advances in NSC Research and Clinical Applications
- Trend Rate Data for NSC Grants, Clinical Trials, Scientific Publications
- Geographic Assessment of NSC Clinical Trial Activity
- Utilization of NSCs Relative to Other Stem Cell Types
- Patent Analysis for the NSC Sector
- NSC Market Size Determinations, including Projections for 2016-2020
- Key Acquisitions and Partnerships within the NSC Sector
- Social Analytics for the NSC Marketplace, including Individual User Data and Aggregate Responses
- Company Profiles for NSC Industry Leaders
- And Much More
Click here to learn more – https://bioinformant.wpengine.com/product/strategic-development-of-neural-stem-cell-products/
About Us
BioInformant is the only research firm that has served the stem cell sector since it emerged. BioInformant has been featured on news outlets including the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, Becton Dickinson, and Thermo Fisher Scientific, BioInformant is your global leader in stem cell industry data.